Gyeonggi-do, South Korea

Jae Seob Jung

USPTO Granted Patents = 3 

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2020-2024

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations by Jae Seob Jung in Cancer Treatment

Introduction

Jae Seob Jung is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of medical science, particularly in cancer treatment. With a total of 3 patents to his name, his work focuses on the production of natural killer cells, which play a crucial role in the immune response against cancer.

Latest Patents

One of Jae Seob Jung's latest patents is a method for producing natural killer cells and a composition for treating cancer. This innovative method involves isolating peripheral blood mononuclear cells (PBMCs) from a blood sample. It further includes isolating CD56+ cells and/or CD3−/CD56+ cells from the PBMCs. The process continues with co-culturing these cells with a combination of feeder cells in the presence of a cytokine. The resulting composition comprises the CD56+ natural killer cells produced by this method along with a cytokine, showcasing a promising approach to cancer treatment.

Career Highlights

Jae Seob Jung is associated with Nkmax Co., Ltd., a company that focuses on developing advanced therapies for cancer treatment. His work has been instrumental in advancing the understanding and application of natural killer cells in clinical settings.

Collaborations

He has collaborated with notable colleagues such as Sang Woo Park and Yong Man Kim, contributing to the innovative research and development in the field of immunotherapy.

Conclusion

Jae Seob Jung's contributions to the field of cancer treatment through his innovative methods for producing natural killer cells highlight the potential of immunotherapy in combating cancer. His work continues to inspire advancements in medical science and offers hope for improved treatment options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…